2023
Targeting galectin-driven regulatory circuits in cancer and fibrosis
(Mariño et al., Nature Reviews Drugs Discovery).
+Info
Major scientific findings
Timeline
2022
Gal-1 prevents plaque formation in atherosclerosis by targeting macrophages and smooth muscle cells.
(Roldán Montero et al., Science Adv.).
+Info
2021
Gal-1 serves as a therapeutic target in intestinal inflammation and colorectal cancer.
(Morosi et al., Science Adv.; Cagnoni et al. PNAS).
+Info
2018
Pathogens thwart immune responses and promote invasion via induction of Gal-1.
(Lujan et al., PNAS.; Poncini et al., J. Immunol.; Davicino et al., J. Immunol; Russo et al, Nat Immunol.).
+Info
2014
Gal-1 promotes vascularization and confers resistance to antiangiogenic therapies.
(Croci et al., Cell; Croci et al., J. Exp. Med.).
+Info
2013
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
(Laderach D, Cancer Research).
+Info
2013
Gal-1 favors breast cancer metastasis via induction of regulatory T cells.
(Dalotto-Moreno et al., Cancer Res.).
+Info
2012
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.
(Croci et al., J. Exp. Med.)
+Info
2012
Gal-1 attenuates neuroinflammation by suppressing microglia activation.
(Starossom et al., Immunity).
+Info
2009
Gal-1 promotes the differentiation of tolerogenic dendritic cells.
(Ilarregui et al., Nature Immunol.).
+Info
2007
Gal-1 protects the fetus from immune attack during pregnancy.
(Blois et al., Nature Med.).
+Info
1999
Gal-1 suppresses rheumatoid arthritis by promoting apoptosis of activated T cells.
(Rabinovich et al., J. Exp. Med.).
+Info
1998
Identification, purification and characterization of Gal-1 in innate and adaptive immune cells.
(Rabinovich et al., J. Immunol).
+Info